Minna Harmanen

Minna Harmanen

Auto-generated profile, based on publicly available information

Minna Harmanen

Faculty of Health Medicine, Institute of Clinical Medicine University of Eastern Finland Kuopio Finland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in British Journal of Haematology
Verified
Journal Article
Open access
MHMinna Harmanen
Minna Harmanen
MHMika Hujo
Mika Hujo
RSReijo Sund
Reijo Sund
MSMarc Sorigue
Marc Sorigue
MKMadiha Khan
Madiha Khan
KOKuittinen Outi
Kuittinen Outi
Summary: Mantle cell lymphoma (MCL) is a rare peripheral B‐cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab‐ and cytarabine‐based immunochemotherapy regimens, the prognosis of the disease has changed dramatically over the last two decades. To assess the real‐world survival of patients with MCL, we used a population‐based cohort of 564 patients with MCL who were diagnosed and treated between 2000 and 2020. Patient data were collected from seven Finnish treatment centres and one Spanish treatment centre. For the entire patient population, we report a 2‐year overall survival (OS) rate of 77%, a 5‐year OS of 58%, and a 10‐year OS of 32%. The estimated median OS was 80 months after diagnosis. MCL is associated with increased mortality across the entire patient population. Additionally, we assessed the survival of patients after MCL relapse with the aim of establishing a cut‐off point of prognostic significance. Based on our statistical analysis of survival after the first relapse, disease progression within 24 months of the initial diagnosis should be considered as a strong indicator of poor prognosis.

8 January 2025 in Hematological Oncology
Verified
Journal Article
Closed access
MHMinna Harmanen
Minna Harmanen
MHMika Hujo
Mika Hujo
RSReijo Sund
Reijo Sund
MSMarc Sorigue
Marc Sorigue
MKMadiha Khan
Madiha Khan
OKOuti Kuittinen
Outi Kuittinen


13 April 2026 in European Journal of Haematology
Verified
Journal Article
Open access
AKAtte Karhu
Atte Karhu
SASara Aronen
Sara Aronen
ARAino Rönkä
Aino Rönkä
KSKaisa Sunela
Kaisa Sunela
TKTuula Klaavuniemi
Tuula Klaavuniemi
KOKuittinen Outi
Kuittinen Outi
T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with THRLBCL remains poorly known. To clarify the risk of CNS relapse in THRLBCL, data for 106 patients with THRLBCL diagnosed between 2000 and 2020 were collected from seven hospitals throughout Finland. The control data consisted of 660 patients with diffuse LBCL (DLBCL) diagnosed and treated in Oulu University Hospital. Most of the patients with THRLBCL and DLBCL presented with advanced stage disease and were classified as high‐intermediate or high‐risk groups based on their IPI score. 368 patients received R‐CHOP as first line therapy. Our data included patients who had received CNS prophylaxis. For the entire patient population, we found a 5‐year CNS relapse risk of 1.04% and 5.29% among patients with THRLBCL and DLBCL, respectively ( p < 0.001). In conclusion, THRLBCL has lowered CNS relapse risk compared to DLBCL.